| 股票简称：华海药业 股票代码：600521 | 公告编号：临 | 号 2025-100 | | --- | --- | --- | | 债券简称：华海转债 债券代码：110076 | | | 浙江华海药业股份有限公司 关于获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华海药业股份有限公司（以下简称"公司"）于近日收到国家药品监督管 理局（以下简称"国家药监局"）核准签发的坎地沙坦酯氢氯噻嗪片（Ⅱ）和注射 用盐酸罗沙替丁醋酸酯的《药品注册证书》，现将相关情况公告如下： 一、坎地沙坦酯氢氯噻嗪片（Ⅱ）相关情况 药品名称：坎地沙坦酯氢氯噻嗪片（Ⅱ） 剂型：片剂 规格：每片含坎地沙坦酯 16mg 与氢氯噻嗪 12.5mg 申请事项：药品注册（境内生产） 药品批准文号：国药准字 H20255456 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符 合药品注册的有关要求，批准注册，发给药品注册证书。 坎地沙坦酯氢氯噻嗪片（Ⅱ）用于治疗高血压。本品不适用于高血压的初始治 疗，本品适 ...

根据国家相关政策，公司坎地沙坦酯氢氯噻嗪片(Ⅱ)和注射用盐酸罗沙替丁醋酸酯按化学药品3类批准 生产可视同通过一致性评价。本次坎地沙坦酯氢氯噻嗪片(Ⅱ)和注射用盐酸罗沙替丁醋酸酯获得国家药 监局的《药品注册证书》，进一步丰富了公司的产品线，有助于提升公司产品的市场竞争力，对公司的 经营发展具有一定积极的作用。 智通财经APP讯，华海药业(600521.SH)发布公告，公司于近日收到国家药品监督管理局(以下简称"国家 药监局")核准签发的坎地沙坦酯氢氯噻嗪片(Ⅱ)和注射用盐酸罗沙替丁醋酸酯的《药品注册证书》。 ...

智通财经APP讯，华海药业(600521.SH)发布公告，公司于近日收到国家药品监督管理局(以下简称"国家 药监局")核准签发的坎地沙坦酯氢氯噻嗪片(Ⅱ)和注射用盐酸罗沙替丁醋酸酯的《药品注册证书》。 根据国家相关政策，公司坎地沙坦酯氢氯噻嗪片(Ⅱ)和注射用盐酸罗沙替丁醋酸酯按化学药品3类批准 生产可视同通过一致性评价。本次坎地沙坦酯氢氯噻嗪片(Ⅱ)和注射用盐酸罗沙替丁醋酸酯获得国家药 监局的《药品注册证书》，进一步丰富了公司的产品线，有助于提升公司产品的市场竞争力，对公司的 经营发展具有一定积极的作用。 ...

华海药业公告，近日收到国家药监局核准签发的坎地沙坦酯氢氯噻嗪片（Ⅱ）和注射用盐酸罗沙替丁醋 酸酯的《药品注册证书》。坎地沙坦酯氢氯噻嗪片（Ⅱ）用于治疗高血压，国内市场销售金额约1.49亿 元。注射用盐酸罗沙替丁醋酸酯用于上消化道出血（由消化性溃疡、急性应激性溃疡、出血性胃炎等引 起）的低危患者，国内市场销售金额约11.8亿元。公司在坎地沙坦酯氢氯噻嗪片研发项目上已投入约 1128万元，在注射用盐酸罗沙替丁醋酸酯研发项目上已投入约431万元。 ...

格隆汇9月16日丨华海药业(600521.SH)公布，公司于近日收到国家药品监督管理局核准签发的坎地沙坦 酯氢氯噻嗪片(Ⅱ)和注射用盐酸罗沙替丁醋酸酯的《药品注册证书》，坎地沙坦酯氢氯噻嗪片(Ⅱ)用于 治疗高血压。本品不适用于高血压的初始治疗，本品适用于单用坎地沙坦酯或氢氯噻嗪不能有效控制血 压的成年人原发性高血压，或两药联合用药同剂量的替代治疗。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ●会议召开时间：2025年9月22日（星期一）16:00-17:00； ●会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.sseinfo.com/）； ●会议召开方式：上证路演中心网络互动； ● 投资者可于2025年9月15日（星期一）至9月19日（星期五）16:00前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱600521@huahaipharm.com进行提问。 公司将在说明会上对投资者普遍关注的问题进行回答。 浙江华海药业股份有限公司（以下简称"公司"）已于2025年8月26日发布公司2025年半年度报告，为便 于广大投资者更全面深入地了解公司2025年半年度经营成果、财务状况，公司计划于2025年9月22日 （星期一）16:00-17:00举行2025年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司 ...

| 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 号 2025-099 | | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | 浙江华海药业股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 9 月 15 日（星期一）至 9 月 19 日（星期五）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 600521@huahaipharm.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 浙江华海药业股份有限公司（以下简称"公司"）已于 2025 年 8 月 26 日发 布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半 年度经营成果、财务状况，公司计划于 2025 年 9 月 22 日（星期一）16:00-17:00 举行 2025 年半年度业绩说明会，就投资者关心的 ...

Core Insights - The market demand for chitosan is increasing due to growing concerns about food safety, healthcare, and environmental protection, with the market size in China projected to reach 758 million yuan in 2024, representing a year-on-year growth of 19.37% [1][7]. Industry Overview - Chitosan is a natural biodegradable biopolymer derived from chitin, primarily sourced from the shells of crustaceans and certain fungi and plants [2][4]. - The unique physical and chemical properties of chitosan, influenced by its degree of deacetylation, allow for a wide range of applications across various sectors [2][4]. Industry Chain - The upstream of the chitosan industry includes raw materials such as crustacean shells, insects, fungi, and chemicals like hydrochloric acid and sodium hydroxide [5]. - The midstream involves the production and manufacturing of chitosan, while the downstream applications span pharmaceuticals, food preservation, cosmetics, environmental protection, agriculture, textiles, and paper [5][6]. Market Size - The chitosan industry in China is expected to grow significantly, with applications in food preservation, medical materials, and as an eco-friendly alternative to traditional plastics [1][7]. Key Companies - Jiangsu Kangting Biotechnology Co., Ltd. is a major player in the chitosan industry, focusing on research, production, and sales, with a wide range of applications in health foods, medical devices, and agriculture [8][9]. - Shandong Weikang Biomedical Technology Co., Ltd. specializes in marine sugar bioengineering, emphasizing research and development in chitosan and its derivatives [9]. Industry Development Trends 1. Continuous technological innovation is crucial for industry upgrades, with new extraction methods like enzyme extraction and supercritical fluid extraction expected to replace traditional methods [10][11]. 2. The application of chitosan is expanding into emerging fields beyond traditional sectors, including its use as a natural preservative and in high-end medical products [10][11]. 3. The industry's strategic value is highlighted by the push for sustainable development and carbon neutrality, with international competition driving technological upgrades and collaborations [11].

Market Overview - The convertible bond market showed positive performance with the Zhongzheng Convertible Bond Index rising by 1.23% to 480.25, with a total trading volume of 76.871 billion [1] - A total of 437 convertible bonds were traded, with 409 increasing in value, 1 remaining flat, and 27 declining [1] Top Performing Convertible Bonds - The top five performing convertible bonds included: - Fushi Convertible Bond (123217) with a rise of 20.0% - Jing 23 Convertible Bond (113669) also up by 20.0% - Jiazhe Convertible Bond (113039) increasing by 17.69% - Chongda Convertible Bond 2 (128131) up by 14.01% - Outong Convertible Bond (not specified) rising by 11.67% [2] Underperforming Convertible Bonds - The five convertible bonds with the largest declines were: - Kaizhong Convertible Bond (113698) down by 3.29% - Yaoshi Convertible Bond (123145) decreasing by 2.92% - Titan Convertible Bond (127096) falling by 2.69% - Huicheng Convertible Bond (not specified) down by 2.04% [2] Corresponding Stock Performance - Among the stocks corresponding to the convertible bonds, 352 stocks rose, 16 remained flat, and 69 declined [1] - The top five performing stocks included: - Si Hui Fushi (300852) with a rise of 19.99% - Jingke Technology (601778) increasing by 10.05% - Chongda Technology (002815) up by 10.01% - Luxshare Precision (not specified) rising by 10.00% - Jingwang Electronics (not specified) also up by 10.00% [4] Declining Stocks - The stocks with the largest declines included: - Titan Shares (not specified) down by 5.64% - Huahai Pharmaceutical (not specified) decreasing by 4.26% - Nenghui Technology (not specified) down by 3.88% - Shouhua Gas (not specified) falling by 2.99% - Shandong Zhanggu (not specified) down by 2.98% [5]

Group 1 - Dematech won a 900 million yuan overseas smart logistics project from a well-known e-commerce giant in Latin America, focusing on intelligent logistics cross-belt sorting systems and related services [1] - Kang En Bei received approval for the registration of short-term financing bonds and medium-term notes, with a total registration amount of 1 billion yuan, valid for two years [1][2] - Zhi Xiang Jin Tai's GR1803 injection for systemic lupus erythematosus clinical trial has been approved by the National Medical Products Administration [2] Group 2 - Jin Da Wei's subsidiary received approval for a veterinary drug product, pyridone, valid from September 3, 2025, to September 2, 2030 [4] - Fu Li Wang's subsidiary plans to invest 500 million yuan in a high-end wire material project, focusing on high-strength prestressed steel strands for various applications [5] - He Li Biological's subsidiary's Class III medical device registration application has been accepted, focusing on natural bone repair materials [12] Group 3 - Lin Yang Energy won a 244 million yuan metering equipment project from Southern Power Grid, expected to positively impact its 2025 and 2026 performance [20] - Sanxia Water plans to absorb its wholly-owned subsidiary, Chongqing Changdian United Energy, with all assets and liabilities to be inherited by Sanxia Water [13] - Tian Cheng Technology canceled the use of 91 million yuan of raised funds for permanent working capital, ensuring no impact on the normal operation of investment projects [24] Group 4 - Baosteel received approval to publicly issue bonds totaling 20 billion yuan to professional investors, valid for 24 months [52] - Tian Kang Biological reported a 10.15% year-on-year increase in pig sales in August, with a total of 263,800 pigs sold [53] - Xinjiang Construction won multiple major projects totaling 4.506 billion yuan, including a 2.4 billion yuan photovoltaic hydrogen synthesis project [18]